AJCN Cancer Health Disparities Conference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Astrup, A.
Right arrow Articles by Quaade, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Astrup, A.
Right arrow Articles by Quaade, F.
Agricola
Right arrow Articles by Astrup, A.
Right arrow Articles by Quaade, F.

American Journal of Clinical Nutrition, Vol 55, 246S-248S, Copyright © 1992 by The American Society for Clinical Nutrition, Inc

REVIEW ARTICLES

Pharmacology of thermogenic drugs

A Astrup, S Toubro, NJ Christensen and F Quaade
Research Department of Human Nutrition, Royal Veterinary and Agricultural University, Copenhagen, Denmark.

Thermogenic combinations of ephedrine with caffeine and newer selective beta 3-agonists are being assessed for the treatment of obesity. The actions of beta-agonists may be multifaceted, with acute stimulation of thermogenic mechanisms in various tissues. During chronic treatment recruitment of brown fat may occur and hypertrophy of skeletal muscle may occur and simultaneously increase lean body tissue and reduce fat mass by stimulation of lipolysis and energy expenditure. The weight- reducing effect of an ephedrine-caffeine combination was superior to placebo treatment during 24 wk of energy restriction in obese women, whereas caffeine and ephedrine separately had no effect. In a second study it was found that ephedrine-caffeine compared with placebo preserved fat-free mass and enhanced fat loss, which could be accounted for both by anorexia (75%) and by increased thermogenesis (25%). The ephedrine-caffeine compound seems useful for the treatment of obesity and may serve as reference in the clinical assessment of new beta- agonists.


This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
L. R Bucci
Selected herbals and human exercise performance
Am. J. Clinical Nutrition, August 1, 2000; 72(2): 624S - 636.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. K. Lee, B. W. H. Cheng, C. T. Che, and D. P. H. Hsieh
Cytotoxicity Assessment of Ma-huang (Ephedra) under Different Conditions of Preparation
Toxicol. Sci., August 1, 2000; 56(2): 424 - 430.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Vaz, G. Jennings, A. Turner, H. Cox, G. Lambert, and M. Esler
Regional Sympathetic Nervous Activity and Oxygen Consumption in Obese Normotensive Human Subjects
Circulation, November 18, 1997; 96(10): 3423 - 3429.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by The American Society for Nutrition